Aptahem AB
Aptahem is a biotechnology company developing RNA-based pharmaceuticals for treating life-threatening acute conditions involving coagulation, inflammation, and tissue damage. Their lead candidate, Apta-1, is in early clinical phase targeting sepsis and other critical inflammatory conditions. The company's mission is to address the global medical need for sepsis treatments, with a vision to deliver best-in-class RNA-based drugs to save lives and improve treatment options.
Industries
Nr. of Employees
small (1-50)
Aptahem AB
Patents
Nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties
US-11110115-B2
View Details
Nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties
US-11110115-B2
View DetailsProducts
Apta-1
Lead RNA aptamer drug candidate developed for sepsis and other acute inflammatory conditions; exhibits antithrombotic, immunomodulatory and tissue-protective properties in preclinical studies and has entered early clinical testing.
Apta-2
Preclinical-stage RNA aptamer candidate under evaluation for inflammatory indications.
Apta-3
Discovery-stage RNA aptamer candidate under early evaluation.
Apta-1
Lead RNA aptamer drug candidate developed for sepsis and other acute inflammatory conditions; exhibits antithrombotic, immunomodulatory and tissue-protective properties in preclinical studies and has entered early clinical testing.
Apta-2
Preclinical-stage RNA aptamer candidate under evaluation for inflammatory indications.
Apta-3
Discovery-stage RNA aptamer candidate under early evaluation.
Services
Design, coordination and oversight of collaborative research projects with academic and industry partners; in-house laboratory studies and data ownership.
Process development, formulation work and coordination with contract manufacturers to produce GMP clinical material and optimize production yields.
Preparation of clinical synopses and trial documentation aligned with regulatory and clinical implementation requirements to support Phase 2 readiness.
Active partnering and licensing efforts to identify collaborators for late-stage development and commercialization, including investor communications.
Design, coordination and oversight of collaborative research projects with academic and industry partners; in-house laboratory studies and data ownership.
Process development, formulation work and coordination with contract manufacturers to produce GMP clinical material and optimize production yields.
Preparation of clinical synopses and trial documentation aligned with regulatory and clinical implementation requirements to support Phase 2 readiness.
Active partnering and licensing efforts to identify collaborators for late-stage development and commercialization, including investor communications.
Expertise Areas
- RNA therapeutics (aptamers)
- Sepsis and acute inflammatory disease therapeutics
- Preclinical pharmacology and animal disease models
- Clinical trial design and execution
Key Technologies
- Aptamer (RNA oligonucleotide) therapeutics
- Oligonucleotide synthesis and scale-up
- Preclinical disease models (ARDS, LPS, sepsis models)
- Randomized double-blind placebo-controlled clinical trials
News & Updates
Shareholders' meeting decisions including approval of the annual report, disposition of the company's results, election of board members, and changes to the articles of association.
Aptahem announced the registration of its rights issue, with BTA (paid subscribed shares) being converted into shares after the registration.
The final outcome of the rights issue shows approximately 49% subscription, raising about SEK 4.8 million before costs.
Aptahem develops innovative RNA-based treatments for severe inflammatory conditions, with their lead candidate Apta-1 in early clinical phase targeting sepsis.
Shareholders' meeting decisions including approval of the annual report, disposition of the company's results, election of board members, and changes to the articles of association.
Aptahem announced the registration of its rights issue, with BTA (paid subscribed shares) being converted into shares after the registration.
The final outcome of the rights issue shows approximately 49% subscription, raising about SEK 4.8 million before costs.
Aptahem develops innovative RNA-based treatments for severe inflammatory conditions, with their lead candidate Apta-1 in early clinical phase targeting sepsis.